Simulating Market Entry Rewards for Antibiotics Development.

Simulasi Imbalan Masuk Pasar untuk Pengembangan Antibiotik.

Clicks: 505
ID: 92960
2018
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #1 of 12 articles by views in the journal of law, medicine & ethics : a journal of the american society of law, medicine & ethics

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
We design an agent based Monte Carlo model of antibiotics research and development (R&D) to explore the effects of the policy intervention known as Market Entry Reward (MER) on the likelihood that an antibiotic entering pre-clinical development reaches the market. By means of sensitivity analysis we explore the interaction between the MER and four key parameters: projected net revenues, R&D costs, venture capitalists discount rates, and large pharmaceutical organizations' financial thresholds. We show that improving revenues may be more efficient than reducing costs, and thus confirm that this pull-based policy intervention effectively stimulates antibiotics R&D.
Kami merancang model Monte Carlo berbasis agen untuk penelitian dan pengembangan (R&D) antibiotik guna mengeksplorasi dampak intervensi kebijakan yang dikenal sebagai *Market Entry Reward* (MER) terhadap kemungkinan antibiotik yang memasuki tahap pengembangan praklinis dapat mencapai pasar. Melalui analisis sensitivitas, kami mengkaji interaksi antara MER dan empat parameter utama: proyeksi pendapatan bersih, biaya R&D, tingkat diskonto pemodal ventura, dan ambang batas finansial organisasi farmasi besar. Kami menunjukkan bahwa peningkatan pendapatan mungkin lebih efisien daripada pengurangan biaya, dan dengan demikian mengonfirmasi bahwa intervensi kebijakan berbasis tarikan (*pull-based*) ini secara efektif menstimulasi R&D antibiotik.
Reference Key
okhravi2018simulatingthe Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Okhravi, Christopher;Callegari, Simone;McKeever, Steve;Kronlid, Carl;Baraldi, Enrico;Lindahl, Olof;Ciabuschi, Francesco;
Journal the journal of law, medicine & ethics : a journal of the american society of law, medicine & ethics
Year 2018
DOI
10.1177/1073110518782913
URL
Keywords
higher education entrepreneurship education entrepreneurial intention business and management education entrepreneurial competency

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.